PARTNERSHIP NEwSLINKMarch 2014

BAyLoR cELEBRATES MATcH DAy 2014Match Day at Baylor College of Medicine and medical schools across the country was held March 21. It represents the culmination of the National Resident Matching Program, which pairs fourth-year medical students with residency programs throughout the country.

At Baylor, 173 fourth-year medical students participated in the match. Results of the match included:

n 79 students who are entering primary care residency programs in the fields of family medicine, pediatrics, internal medicine, medicine/pediatrics, obstetrics and gynecology or emergency medicine. This represents 45 percent of the students participating in the match.

n 45 students who matched with programs at Baylor College of Medicine, and 70 who matched with residency programs in Texas.

At Baylor, Match Day is a special event where students and their families join with faculty and others at Baylor in celebration of their medical career journey. Festive balloons lead the way through the halls of Baylor to the courtyard, where the event is held.

After remarks from Baylor leadership and class president Ben Ma, students count down to 11 a.m. sharp, when they grab the

continued on page 2

NEw BAyLoR LEADERSHIP

Two new key members of Baylor College of Medicine’s academic leadership team are now on board. These new leaders bring proven track records in their fields and

excellent leadership sills. They understand our vision for the future and will be a perfect fit at Baylor.

Dr. Roger Zoorob

Dr. Roger J. Zoorob was named the Richard M. Kleberg Sr. Chair of Family and Community Medicine at Baylor College of Medicine, and started in the position March 16.

He joins Baylor from Meharry Medical College in Nashville, Tenn., where he was chair of the department of family and community medicine and a member of the Center for Women’s Health Research.

Zoorob earned his medical and master’s of public health degrees from the American University of Beirut in Lebanon. He completed residency

NEwS fRoM THE PARTNERSHIP

SAvE THE DATE!2013-2014 Partnership for Baylor College of Medicine Educational

Luncheon SeriesJunior League of Houston

1811 Briar Oaks Lane11:15 a.m. – Registration

11:45 a.m. – Program and luncheon

Stay in the Game Dr. Thomas Hunt III

May 13, 2014

continued on page 2

Dr. Roger Zoorob

Match Day 2014 at Baylor college of Medicine

2

STuDy PoINTS wAy To PoTENTIAL NEw TREATMENT foR BRITTLE BoNE DISEASE

Patients with osteogenesis imperfecta (brittle bone disease) treated with teriparatide, a form of parathyroid

hormone approved for treatment of women with osteoporosis, had stronger bones in the lower spine

and the hip when compared to a group of similar patients who received placebo or an inactive medicine, said researchers in a report that appeared online in

the Journal of Clinical Investigation.

“The treatment worked best in patients with a milder form of the disorder,” said Dr. Brendan Lee, the Robert and Janice McNair Endowed Chair in Molecular and Human Genetics at Baylor and an author of the study. “We hope that larger studies using this drug will be undertaken to determine whether it can also reduce the risk of fracture.” He is also co-director of the Rolanette and Berdon Lawrence Bone Disease Program of Texas and a Howard Hughes Medical Institute investigator.

“Repurposing of drugs or discovering new indications for medications that already have FDA approval, is an efficient way of advancing therapies for rare disorders”

said Dr. Sandesh CS Nagamani, assistant professor of Molecular and Human Genetics and the lead clinical

investigator at Baylor for the study. “Our findings that anabolic bone therapy is likely to be more beneficial

in patients with mild forms of osteogenesis imperfecta is an example for how well-controlled studies can help

personalize therapy.”

Nagamani is the director for Clinic and Metabolic Disorders of Bone and a member of the Rolanette and Berdon Lawrence

Bone Disease Program of Texas.

Osteogenesis imperfecta is a genetic disorder in which the bones of those who have the problem are fragile and easily broken.

The lifelong disease exists in several forms of varying severity. Those who benefited most from the drug in this study had type

1, a mild form of the disorder. It is estimated that between 25,000 and 50,000 people in the United States suffer from osteogenesis

imperfecta.

This is the largest controlled clinical trial ever performed in adult patients with the disorder. This is the first time a drug like teriparatide,

a bone anabolic therapy that changes the way bone is remodeled, has been studied in this population.

To read more about the study, visit the Baylor College of Medicine news site at www.bcm.edu/news.

envelopes from the colorful match board that reveal where they will be conducting their residency training.

“It’s a great day at Baylor College of Medicine. When we think of the fun times here, we think of White Coat Ceremony as students are starting medical school, we think of graduation and, of course, we think of Match Day,” said Baylor President and CEO Dr. Paul Klotman.

But he reminded students that Match Day is not the end of the journey. Drawing an analogy to car racing, he said Match Day is more like determining pole position but students still need to perform well in the race.

“You can match to your No. 1 choice but if you don’t go there and perform to the best of your abilities and training, you won’t do as well as someone who got their fourth choice.”

Klotman told the students they will find that they are better trained than everyone else. “Practice the Baylor way, and be proud of the organization that you came from.”

Also speaking at the event were Drs. Dr. Alicia Monroe, senior dean of education, Stephen Greenberg, senior vice president and dean of medical education, and Mary Brandt, asso-ciate dean of student affairs.

MATcH DAy 2014 continued from page 1 training at Anderson Memorial Hospital in South Carolina

and a Faculty Development Fellowship at the University of Kentucky in Lexington.

His areas of interest include fetal alcohol syndrome, using behavior modification and health services research in the

areas of chronic diseases such as diabetes, hypertension and hyperlipidemia; adolescent and adult immunization; case-

based learning strategies in graduate medical education; and translational and community based participatory research.

Dr. Donald Donovan

Dr. Donald T. Donovan was named the Olga Keith Wiess and Chair of the Bobby R. Alford Department of Otolaryngology – Head and Neck Surgery after leading the department as interim chair since 2010.

Donovan began his medical career at Baylor as a student, earning his medical degree, and then later completing his residency in surgery and otolaryngology. After working as a Special Fellow with Dr. John J. Conley in head and neck oncology, plastic and reconstructive surgery in New York, Donovan joined the faculty at Baylor.

He specializes in head and neck tumors, laryngeal/voice disorders, endoscopic sinus surgery and thyroid cancer, and sees patients in the Smith Tower. Highly

regarded for his clinical expertise, he has been recognized annually by Best Doctors in America since 1998.

He will lead plans to expand otolaryngology services to the McNair Campus in January 2015.

NEw LEADERSHIP continued from page 1

Dr. Brendan Lee

Dr. Donald Donovan